Latest:
Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jacob Sands, MD
Latest:
Monitoring Patients With RET-Positive NSCLC
Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors.
Jad Hayes, MS
Latest:
Can New Oncology Payment Programs Help Stabilize Medicare?
Studies have raised doubts about the value Medicare and other payers are getting for the care they pay for, including in oncology. This has intensified the demand for new value-based care models such as the Merit-based Incentive Payment System and the Oncology Care Model.
Jae Park, MD
Latest:
Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.
Jae Y. Kim, MD
Latest:
Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung Cancer
Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.